- Five of those drugs have been approved for use in additional cancer indications; clinical trials are underway for the other 14 FDA-approved treatments for additional indications.
- Survival rates for children with lymphocytic leukemia (the most common childhood cancer) have risen from 3% to 90% since the 1960s.
- Hodgkin lymphoma patient survival rates have doubled (now 88%) since the 1960s.
To find out more about supporting Team Atherio or participating in Light The Night Walk visit http://pages.lightthenight.org/ncfl/Jacksonv13/teamatherio#Welcome-to-our-Teams-Homepage
Atherio is a leading global technology services company providing end-to-end technology enabled business solutions to the enterprise. Atherio is differentiated in the market through their “maniacal focus on client satisfaction”, market driven service offerings and an unsurpassed knowledge of the industries & vertical markets they serve. http://www.Atherio.com
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit http://www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Atherio, Red River Solutions, Dr.Healthcheck and NVISH are registered trademarks of Atherio, Inc. and/or its affiliates. Other names may be trademarks of their respective owners.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11208368.htm